{"id":"nov03","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NOV03 is a nucleoside analog that inhibits viral replication by interfering with viral DNA synthesis.","oneSentence":"NOV03 is an investigational antiviral medication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:26.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT05723770","phase":"PHASE4","title":"Effects of NOV03 on the Tear Film","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2023-08-14","conditions":"Dry Eye Disease (DED)","enrollment":33},{"nctId":"NCT04139798","phase":"PHASE3","title":"Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2020-07-20","conditions":"Dry Eye Disease (DED)","enrollment":599},{"nctId":"NCT04567329","phase":"PHASE3","title":"Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2020-11-18","conditions":"Dry Eye Disease","enrollment":620},{"nctId":"NCT04140227","phase":"PHASE3","title":"Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2020-09-24","conditions":"Dry Eye Disease (DED)","enrollment":256},{"nctId":"NCT03333057","phase":"PHASE2","title":"Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2018-01-03","conditions":"Dry Eye Disease (DED)","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NOV03","genericName":"NOV03","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NOV03 is an investigational antiviral medication. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}